Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update

Provided By PR Newswire

Last update: May 13, 2022

TORRANCE, Calif., May 13, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three months ended March 31, 2022 and provided a business update.